mianserin has been researched along with Recrudescence in 30 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the prophylactic effect of mianserin on depressive episode, 26 patients with recurrent depression were randomly allocated on a double-blind basis to treatment with either inactive placebo (PL group) or mianserin in daily dose of 20-60 mg (MIA group) for 18 months and the frequencies or durations of depressive episode during the treatment were compared between the two groups." | 9.07 | [A controlled study of the prophylactic effect of mianserin and placebo in recurrent depression]. ( Hazama, H; Kamase, H; Kishimoto, A; Kunimoto, N; Mizukawa, R; Tanaka, K, 1993) |
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 7.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| " After one year, the dosage of mianserin was increased to 30 mg t." | 6.64 | Mianserin and lithium in the prophylaxis of depression. ( Bailey, J; Coppen, A; Ghose, K; Peet, M; Rao, R, 1978) |
| "Depression is a common problem in elderly patients and frequently is treated with antidepressants." | 5.33 | Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006) |
| "To examine the prophylactic effect of mianserin on depressive episode, 26 patients with recurrent depression were randomly allocated on a double-blind basis to treatment with either inactive placebo (PL group) or mianserin in daily dose of 20-60 mg (MIA group) for 18 months and the frequencies or durations of depressive episode during the treatment were compared between the two groups." | 5.07 | [A controlled study of the prophylactic effect of mianserin and placebo in recurrent depression]. ( Hazama, H; Kamase, H; Kishimoto, A; Kunimoto, N; Mizukawa, R; Tanaka, K, 1993) |
| " Authors report a case of a 65-year old male patient who was treated with venlafaxine-mirtazapine combination for recurrent depression." | 3.79 | [Antidepressant treatment associated hyponatremia -- case report]. ( Bognár, Z; Gazdag, G; Vonyik, G, 2013) |
| "We present a case of recurrent hypothermia in concordant monozygotic twins born to a mirtazapine treated mother." | 3.74 | Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy. ( Klinger, G; Merlob, P; Sokolover, N, 2008) |
| " Overall, 35-42% of esmirtazapine-treated patients had adverse events (AEs) versus 29% in the placebo group." | 2.80 | Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial. ( Ivgy-May, N; Krystal, A; Roth, T; Ruwe, F, 2015) |
| "Prior studies have suggested that major depressive disorder (MDD) with pre-adult onset represents a distinct subtype with greater symptom severity and higher rates of suicidal ideation." | 2.78 | Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. ( Balasubramani, GK; Kurian, B; Rush, AJ; Sung, SC; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2013) |
| "The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy." | 2.77 | Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Mirtazapine was then initiated for residual depressive symptoms." | 2.71 | Migraine headache prophylaxis and treatment with low-dose mirtazapine. ( Lévy, E; Margolese, HC, 2003) |
| "The ratio between patients with recurrence and total patients (recurrence ratio) was lower in the mianserin-treated group throughout the study, and the intergroup difference from the 3rd to the 18th month was significant." | 2.67 | Prophylactic effect of mianserin on recurrent depression. ( Hazama, H; Kamase, H; Kishimoto, A; Kunimoto, N; Matsuzaki, F; Mizukawa, R; Tanaka, K, 1994) |
| " After one year, the dosage of mianserin was increased to 30 mg t." | 2.64 | Mianserin and lithium in the prophylaxis of depression. ( Bailey, J; Coppen, A; Ghose, K; Peet, M; Rao, R, 1978) |
| "Mirtazapine is an antidepressant with mode of action different from other currently available antidepressants." | 2.40 | Mirtazapine: other indications. ( Falkai, P, 1999) |
| "Depression is a common problem in elderly patients and frequently is treated with antidepressants." | 1.33 | Recurrent hyponatremia associated with citalopram and mirtazapine. ( Akcay, A; Bavbek, N; Kargili, A; Kaya, A, 2006) |
| "Mirtazapine is a noradrenergic with specific selective serotoninergic antidepressant." | 1.30 | Mirtazapine in recurrent brief depression. ( Aschauer, HN; de Zwaan, M; Kasper, S; Pezawas, L; Stamenkovic, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (10.00) | 18.7374 |
| 1990's | 8 (26.67) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 8 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bognár, Z | 1 |
| Vonyik, G | 1 |
| Gazdag, G | 1 |
| Warden, D | 2 |
| Trivedi, MH | 3 |
| Carmody, T | 1 |
| Toups, M | 1 |
| Zisook, S | 3 |
| Lesser, I | 1 |
| Myers, A | 1 |
| Kurian, KR | 1 |
| Morris, D | 1 |
| Rush, AJ | 3 |
| Ivgy-May, N | 1 |
| Ruwe, F | 1 |
| Krystal, A | 1 |
| Roth, T | 1 |
| Naples, JG | 1 |
| Kotlarczyk, MP | 1 |
| Perera, S | 1 |
| Greenspan, SL | 1 |
| Hanlon, JT | 1 |
| Sokolover, N | 1 |
| Merlob, P | 1 |
| Klinger, G | 1 |
| Benedict, A | 1 |
| Arellano, J | 1 |
| De Cock, E | 1 |
| Baird, J | 1 |
| Grønli, O | 1 |
| Stensland, GØ | 1 |
| Wynn, R | 1 |
| Olstad, R | 1 |
| Mischo, M | 1 |
| Nigg, C | 1 |
| Kiss, A | 1 |
| Davis, LL | 1 |
| Pilkinton, P | 1 |
| Wisniewski, SR | 2 |
| Gaynes, BN | 1 |
| Howland, RH | 1 |
| Balasubramani, GK | 2 |
| Fava, M | 1 |
| Sung, SC | 1 |
| Kurian, B | 1 |
| Lévy, E | 1 |
| Margolese, HC | 1 |
| Nash, JR | 1 |
| Wilson, SJ | 1 |
| Potokar, JP | 1 |
| Nutt, DJ | 1 |
| Bavbek, N | 1 |
| Kargili, A | 1 |
| Akcay, A | 1 |
| Kaya, A | 1 |
| Elstner, S | 1 |
| Burian, R | 1 |
| Diefenbacher, A | 1 |
| Montgomery, SA | 1 |
| Roy, D | 1 |
| Montgomery, DB | 1 |
| Kishimoto, A | 2 |
| Mizukawa, R | 2 |
| Matsuzaki, F | 1 |
| Hazama, H | 2 |
| Kamase, H | 2 |
| Tanaka, K | 2 |
| Kunimoto, N | 2 |
| Nisijima, K | 1 |
| Oyafuso, K | 1 |
| Shimada, T | 1 |
| Hosino, H | 1 |
| Ishiguro, T | 1 |
| Bottlender, R | 1 |
| Erfurth, A | 1 |
| Hoff, P | 1 |
| Möller, HJ | 1 |
| Stamenkovic, M | 1 |
| Pezawas, L | 1 |
| de Zwaan, M | 1 |
| Aschauer, HN | 1 |
| Kasper, S | 1 |
| Falkai, P | 1 |
| Nierenberg, AA | 2 |
| Wright, EC | 1 |
| Moustgaard, G | 1 |
| Good, C | 1 |
| Petersen, C | 1 |
| Thase, ME | 1 |
| Keller, MB | 1 |
| Panagides, J | 1 |
| Delgado, PL | 1 |
| Moreno, FA | 1 |
| Onate, L | 1 |
| Gelenberg, AJ | 1 |
| Coppen, A | 1 |
| Ghose, K | 1 |
| Rao, R | 1 |
| Bailey, J | 1 |
| Peet, M | 1 |
| Haefeli, WE | 1 |
| Schoenenberger, RA | 1 |
| Scholer, A | 1 |
| Altamura, AC | 1 |
| Mauri, M | 1 |
| Guercetti, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Six-Week Double-Blind Randomized, Placebo-Controlled, Parallel Group, Efficacy and Safety, Sleep Lab Trial With Org 50081 in Patients With Chronic Primary Insomnia[NCT00506389] | Phase 3 | 419 participants (Actual) | Interventional | 2007-06-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
LPS was defined as the time in minutes from lights out to the first 20 consecutive epochs scored as sleep as measured by PSG. LPS was calculated as the mean of Nights 1, 15, and 36. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 28.7 |
| Esmirtazapine 4.5 mg | 26.1 |
| Placebo | 40.5 |
TST was defined as the total amount of time in minutes that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary. TST values over the 6 week In-Treatment Period were averaged for each participant, and average TST was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were available was used in the analysis. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 384.6 |
| Esmirtazapine 4.5 mg | 384.6 |
| Placebo | 351.6 |
WASO was defined as the total objective time awake after the onset of persistent sleep until the end of the 8-hour sleep cycle period as measured by polysomnography (PSG). WASO was calculated as the mean of Nights 1, 15, and 36. (NCT00506389)
Timeframe: From Day 1 to Day 36
| Intervention | Minutes (Mean) |
|---|---|
| Esmirtazapine 3.0 mg | 45.6 |
| Esmirtazapine 4.5 mg | 45.5 |
| Placebo | 76.1 |
4 reviews available for mianserin and Recrudescence
| Article | Year |
|---|---|
[Depression].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C | 2010 |
[Depression in family practice].
Topics: Age Factors; Aged; Antidepressive Agents, Tricyclic; Cognitive Behavioral Therapy; Depressive Disord | 2007 |
Mirtazapine: other indications.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Clinical Trials as Topic; Depressive Dis | 1999 |
Evolution of remission as the new standard in the treatment of depression.
Topics: Antidepressive Agents; Clinical Trials as Topic; Clomipramine; Cyclohexanols; Depressive Disorder; F | 1999 |
11 trials available for mianserin and Recrudescence
| Article | Year |
|---|---|
Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care.
Topics: Adult; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive Diso | 2014 |
Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedative | 2015 |
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive | 2012 |
Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bupropion; Child Ab | 2013 |
Migraine headache prophylaxis and treatment with low-dose mirtazapine.
Topics: Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; Mianserin; Migraine Di | 2003 |
The prevention of recurrent suicidal acts.
Topics: Adult; Borderline Personality Disorder; Depressive Disorder; Dibenzazepines; Female; Histrionic Pers | 1983 |
Prophylactic effect of mianserin on recurrent depression.
Topics: Adult; Aged; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hum | 1994 |
[A controlled study of the prophylactic effect of mianserin and placebo in recurrent depression].
Topics: Adult; Depression; Double-Blind Method; Female; Humans; Male; Mianserin; Middle Aged; Premedication; | 1993 |
Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.
Topics: Adult; Chronic Disease; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; | 2001 |
Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Second-Generation; Catecholamines; | 2002 |
Mianserin and lithium in the prophylaxis of depression.
Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Depression; Dibenzazepines; Double-Blin | 1978 |
15 other studies available for mianserin and Recrudescence
| Article | Year |
|---|---|
[Antidepressant treatment associated hyponatremia -- case report].
Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Critical Care; Cyc | 2013 |
Non-tricyclic and Non-selective Serotonin Reuptake Inhibitor Antidepressants and Recurrent Falls in Frail Older Women.
Topics: Accidental Falls; Aged, 80 and over; Antidepressive Agents; Bupropion; Female; Frail Elderly; Humans | 2016 |
Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Body Temperature Regulation; Female; Fol | 2008 |
Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
Topics: Cost-Benefit Analysis; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; Duloxetine H | 2010 |
Neurotrophic factors in serum following ECT: a pilot study.
Topics: Adult; Aged; Aged, 80 and over; Bipolar Disorder; Combined Modality Therapy; Cyclohexanols; Depressi | 2009 |
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Clonidine; Drug Administration Schedule; Hu | 2003 |
Recurrent hyponatremia associated with citalopram and mirtazapine.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Depression; Diagnosis, Di | 2006 |
Cerebrospinal fluid monoamine metabolism in a case of neuroleptic malignant syndrome improved by electroconvulsive therapy.
Topics: Antidepressive Agents; Antipsychotic Agents; Depressive Disorder; Electroconvulsive Therapy; Female; | 1996 |
[Mianserin-induced hypertension 2 weeks after discontinuation of tranylcypromine].
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Cardiomyopathy, Dilated; Depressive | 1997 |
Mirtazapine in recurrent brief depression.
Topics: Administration, Oral; Adult; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Humans; | 1998 |
Treatment-refractory depression successfully treated with the combination of mirtazapine and lithium.
Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Depressive Disorder, Major; Drug Therapy, Combin | 2000 |
SSRI and mirtazapine in PTSD.
Topics: Adrenergic alpha-Antagonists; Child; Child Abuse, Sexual; Drug Therapy, Combination; Female; Humans; | 2001 |
[Depressive disorders. A third have a chronic course].
Topics: Antidepressive Agents, Tricyclic; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Dr | 2001 |
Recurrent ventricular fibrillation in mianserin intoxication.
Topics: Humans; Male; Mianserin; Middle Aged; Recurrence; Ventricular Fibrillation | 1991 |
Prophylactic treatment with mianserin, therapy adherence and plasma monitoring. A case report.
Topics: Depressive Disorder; Female; Humans; Mianserin; Middle Aged; Recurrence; Suicide Prevention | 1986 |